ArticleBMC cancer2026

Trials in progress: CARMAN - study protocol of a randomized controlled, international, multicenter, open-label phase II trial evaluating early treatment intensification in patients with high-risk mantle cell lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with rituximab and ibrutinib and 6 months ibrutinib maintenance as compared to standard of care induction and maintenance.

Marie-Kristin Tilch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.